
-
Freeman at the double as slick Lions romp past Reds 52-12
-
India's Jaiswal on the attack against England in second Test
-
Liverpool defender Quansah signs for Bayer Leverkusen
-
Alcaraz aims to avoid giant-killing after Wimbledon seeds tumble
-
Freeman at the double as Lions sweep past Queensland Reds 52-12
-
Iran ends cooperation with UN nuclear watchdog after Israel, US strikes
-
Matildas' defender Carpenter leaves Lyon for Chelsea
-
Public or private? Funding debate splits reeling aid sector
-
Stocks diverge as tariffs deadline looms
-
EU unveils long-delayed 2040 climate target -- with wiggle room
-
Central Europe swelters as heatwave moves east
-
Hong Kong to regain IPO crown this year, say PwC and Deloitte
-
Iran suspends cooperation with UN nuclear watchdog
-
Israel's top diplomat urges seizing chance after Trump ceasefire push
-
Australia cancels Kanye West visa over 'Heil Hitler' song
-
Israel FM calls to seize opportunity as Trump pushes for Gaza ceasefire
-
Fire that closed Heathrow traced to unrepaired transformer
-
Gaza rescuers say Israeli strikes kill 14 as Trump teases ceasefire push
-
Asian markets mixed as trade deal cut-off looms
-
Dalai Lama says he will have successor after his death
-
Demining Ukraine: from drones to risking it with a rake
-
Eggs en Provence: France's unique dinosaur egg trove
-
'I lost my battle': warming sea killing Albania fishing
-
Combs Trial: Day three of jury debate after partial verdict reached
-
Giant Trump tax bill faces make-or-break vote in Congress
-
Oasis: five favourite hits
-
'Finally': Oasis fans, young and old, gear up for reunion
-
North Korea opens massive beach resort: state media
-
'No roof' to Savea ability for ex-All Black Kaino before France Tests
-
Alcaraz faces amateur hour against young Brit at Wimbledon
-
'Writing is thinking': do students who use ChatGPT learn less?
-
Australian airline Qantas says hit by 'significant' cyberattack
-
India exporters cautiously optimistic as US tariff deadline looms
-
Real Madrid oust Juventus as Dortmund reach Club World Cup quarters
-
Relief coming for Europe after brutal heatwave
-
Fate of major trade deal with EU hangs over Mercosur summit
-
Thai veteran politician set for single day as acting PM
-
Guirassy double as Dortmund down Monterrey to reach Club World Cup quarters
-
BTS agency confirms superstars' 2026 album, tour
-
US halting some shipments of military aid to Ukraine
-
ALMA lets astronomers see building blocks of early galaxies
-
Philippines biodiversity hotspot pushes back on mining
-
Deal or no deal: What happens with Trump's July tariff deadline?
-
Canada turns to drones for reforestation after wildfires
-
US, Japan, India, Australia pledge mineral cooperation on China jitters
-
Son of kingpin 'El Chapo' to plead guilty to drug trafficking in US
-
Viemed Completes Acquisition of Lehan's Medical Equipment Anticipates Updating its Full Year 2025 Outlook for the Acquisition with Second Quarter 2025 Financial Results
-
Greenlane's Leading Wholesale Platform Provides Exclusive Fulfillment of All Safety Strips Tech Corp's. Harm Reduction Solutions Offered via its Direct-to-Consumer Ecommerce Store
-
Camber Energy Announces Positive Test Results for Waste Treatment System
-
Kingfisher Announces Drilling is Underway at HWY 37 Project, Golden Triangle

Oprah's WeightWatchers exit sends stock tumbling
Oprah Winfrey's announcement that she is leaving the board of WeightWatchers sent the company's shares tumbling Thursday -- the latest sign of trouble for the brand as it struggles to compete with new weight-loss drugs.
The departure of Winfrey, who has often addressed her own weight issues during her high profile television and business career, comes after she revealed last year that she was taking prescription anti-obesity medication.
A new generation of anti-diabetic drugs, which include Ozempic, Wegovy and Mounjaro, have been hailed as an effective treatment for obesity -- driving up the valuations of manufacturers such as Denmark's Novo Nordisk and America's Eli Lilly.
Upon Winfrey's departure, WeightWatchers stock plummeted on Wall Street, dropping 24 percent during the day before paring some losses to close 18 percent lower.
"Director Oprah Winfrey has decided not to stand for reelection at the company's upcoming annual meeting of shareholders," WeightWatchers said in a statement Thursday.
The company confirmed that Winfrey will donate her WeightWatchers stock -- the value of which was not disclosed -- to the National Museum of African American History and Culture (NMAAHC).
"Ms. Winfrey is making the donation to support the NMAAHC's goal to promote and highlight the contributions of African Americans, and to eliminate any perceived conflict of interest around her taking weight-loss medications," the statement said.
Winfrey presides over a vast business empire and has long promoted health projects, including in her role as the leading spokesperson for WeightWatchers -- which she previously credited with her own dramatic weight-loss.
Created in the 1960s, WeightWatchers, which offers dietary programs on a subscription basis, is now facing competition from the new, albeit expensive, drugs.
In an attempt to stem a decline in membership, it has sought to offer support for people taking drugs like Ozempic that mimic the appetite-reducing hormone GLP-1.
WeightWatchers announced a loss of $112 million in 2023 on sales that fell 14.5 percent to $889 million, and said it expects further declines this year.
Winfrey, 70, who joined the board in 2015, said she will continue to collaborate with WeightWatchers.
"I plan to participate in a number of public forums and events where I will be a vocal advocate in advancing this conversation," Winfrey said, according to the company statement.
Winfrey's colossal influence ranges from politics -- she notably endorsed Barack Obama as president -- to her book club, which has created many instant bestsellers in a phenomenon known as the "Oprah Effect."
P.M.Smith--AMWN